Phase II/III ADC Data in Gynaecological Cancers & Ovarian Cancer: From Platinum Resistant Disease Towards Earlier Lines & Combination Regimens
9:05 am - Monday 8th March 2027
- What the current phase II/III dataset in ovarian, endometrial and cervical cancer tells us about efficacy and tolerability in practice
- The move from late-line to earlier-line and combination settings, and what this changes for trial design and patient selection
- Practical lessons from running these studies at site level, including recruitment and safety management
